Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Esperion Therapeutics Inc (Esperion) is a commercial stage biopharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol-lowering therapies. Its products include NEXLETOL for reducing the risk of myocardial infarction and coronary revascularization in adults who are statin-intolerant or unable to take statins. The company also offers NEXLIZET. Esperion pipeline product includes ATP citrate lyase inhibitors (ACLYi) for primary sclerosing cholangitis and renal disease. The company also developing NILEMDO and NUSTENDI for other indications. Esperion is headquartered in Ann Arbor, Michigan, the US.
Headquarters
United States of America
Address
Suite 150, 3891 Ranchero Drive, Ann Arbor, Michigan, 48180
Website
www.esperion.com
No of Employees
294
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ESPR (NASD)
Revenue (2024)
$403.1M
21.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
56.2%
(2024 vs 2023)
Market Cap*
$814.3M
Net Profit Margin (2024)
XYZ
63.8%
(2024 vs 2023)
* As of and is in US$
Esperion Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Nexletol Tablets: Myocardial Infarction and Coronary Revascularization | NEXLETOL |
| Nexlizet Tablets | NEXLIZET |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, the company signed an agreement to be acquired by ARCHIMED, an investment firm. |
| 2026 | Acquisitions/Mergers/Takeovers | In April, the company acquired Corstasis Therapeutics, a biopharmaceutical company. |
| 2025 | Contracts/Agreements | In June, the company entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited delaying launch of NEXLETOL in the US. |
Competitor Comparison
| Key Parameters | Esperion Therapeutics Inc | Merck & Co Inc | Pfizer Inc | AbbVie Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Ann Arbor | Rahway | New York City | North Chicago | Cambridge |
| State/Province | Michigan | New Jersey | New York | Illinois | Cambridgeshire |
| No. of Employees | 294 | 75,000 | 75,000 | 57,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| J. Martin Carroll | Chairman | Executive Board | 2022 | 76 |
| Sheldon L. Koenig | Director; President; Chief Executive Officer | Executive Board | 2021 | 60 |
| Benjamin Halladay | Chief Financial Officer | Senior Management | 2022 | 40 |
| John B. Harlow | Chief Commercial Officer | Senior Management | 2025 | 50 |
| Glenn Brame | Chief Technical Operations Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer